The company posted net loss of $176.1m, or $0.87 loss per diluted share, compared to $165.27m, or $0.83 loss per diluted share, for the same period last year.
For the first quarter of 2011, Vertex Pharma’s loss from operations was $159.9m, compared to 160.28m, for the same period in the prior year.
Vertex Pharma chairman, president and CEO Matthew Emmens said their progress in recent months with both INCIVEK for people with hepatitis C and VX-770 for people with cystic fibrosis marks a significant step toward Vertex becoming a company capable of discovering, developing and launching innovative new medicines for serious diseases.